NCT01103388View on ClinicalTrials.gov

Rituximab Maintenance After Autologous Transplantation

PHASE3TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

August 31, 2003

Primary Completion Date

April 30, 2006

Study Completion Date

April 30, 2010

Conditions
Non-Hodgkin's Lymphoma
Interventions
DRUG

Rituximab

375 mg/m\^2 by vein (IV) in 4 weekly doses (1 cycle) every 6 months for 4 cycles.

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER